• Yong Il Hwang, Yong Bum Park, Yeon Mok Oh, Ji Hyun Lee, Tae Hyung Kim, Kwang Ha Yoo, Hyoung Kyu Yoon, Chin Kook Rhee, Deog Kyeom Kim, Kyeong Cheol Shin, Sang Yeub Lee, and Ki-Suck Jung.
• Department of Pulmonary, Allergy and Critical Care Medicine, Hallym University Medical Center, Hallym University College of Medicine, Anyang, Korea.
• J. Korean Med. Sci. 2014 Aug 1; 29 (8): 1108-12.

AbstractThe purpose of this study was to compare the Korean COPD guideline to GOLD consensus report in terms of acute exacerbation. A total of 361 patients were enrolled in this study, and 16.9% of them experienced acute exacerbation during the follow-up. A total of 6.3% of patients in GOLD A, 9.5% in GOLD B, 7.7% in GOLD C and 17.0% of GOLD D experienced exacerbation during the first year of follow-up, respectively (P=0.09). There was no one who experienced exacerbation during the first year of follow-up in the Korean group 'ga'. The 12-month exacerbation rates of Korean group 'na' and 'da' were 4.5% and 16.0%, respectively (P<0.001). We explore the experience of exacerbation in patients with change of their risk group after applying Korean COPD guideline. A total of 16.0% of the patients who were reclassified from GOLD A to Korean group 'da' experienced acute exacerbation,and 15.3% from GOLD B to Korean group 'da' experienced acute exacerbation. In summary, the Korean COPD guideline is useful to differentiate the high risk from low risk for exacerbation in terms of spirometry. This indicates that application of Korean COPD guideline is appropriate to treat Korean COPD patients.

24 keywords...

hide…